DDInter1173 DDInter1376
An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methohexital {u} (Compound) resembles {v} (Compound) Pentobarbital
Methohexital {u} (Compound) resembles {v} (Compound) Thiamylal
Methohexital {u} (Compound) binds {v} (Gene) GABRG2
Methohexital {u} (Compound) is included by {v} (Pharmacologic Class) Barbiturates
Methohexital {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Methohexital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Methohexital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Methohexital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procarbazine
Methohexital {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Methohexital (Compound) resembles Pentobarbital (Compound)
Methohexital (Compound) resembles Thiamylal (Compound)
Methohexital (Compound) binds GABRG2 (Gene)
Methohexital (Compound) is included by Barbiturates (Pharmacologic Class)
Methohexital (Compound) causes Salivary hypersecretion (Side Effect)
Methohexital may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Methohexital may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Methohexital may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Methohexital may lead to a major life threatening interaction when taken with Warfarin